Exploring the sequence features determining amyloidosis in human antibody light chains

Abstract The light chain (AL) amyloidosis is caused by the aggregation of light chain of antibodies into amyloid fibrils. There are plenty of computational resources available for the prediction of short aggregation-prone regions within proteins. However, it is still a challenging task to predict th...

Full description

Bibliographic Details
Main Authors: Puneet Rawat, R. Prabakaran, Sandeep Kumar, M. Michael Gromiha
Format: Article
Language:English
Published: Nature Publishing Group 2021-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-93019-9
id doaj-4fa62a20ac6040f6894d6f47565edcc3
record_format Article
spelling doaj-4fa62a20ac6040f6894d6f47565edcc32021-07-04T11:29:20ZengNature Publishing GroupScientific Reports2045-23222021-07-0111111110.1038/s41598-021-93019-9Exploring the sequence features determining amyloidosis in human antibody light chainsPuneet Rawat0R. Prabakaran1Sandeep Kumar2M. Michael Gromiha3Protein Bioinformatics Lab, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology MadrasProtein Bioinformatics Lab, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology MadrasBiotherapeutics Discovery, Boehringer-Ingelheim Inc.Protein Bioinformatics Lab, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology MadrasAbstract The light chain (AL) amyloidosis is caused by the aggregation of light chain of antibodies into amyloid fibrils. There are plenty of computational resources available for the prediction of short aggregation-prone regions within proteins. However, it is still a challenging task to predict the amyloidogenic nature of the whole protein using sequence/structure information. In the case of antibody light chains, common architecture and known binding sites can provide vital information for the prediction of amyloidogenicity at physiological conditions. Here, in this work, we have compared classical sequence-based, aggregation-related features (such as hydrophobicity, presence of gatekeeper residues, disorderness, β-propensity, etc.) calculated for the CDR, FR or VL regions of amyloidogenic and non-amyloidogenic antibody light chains and implemented the insights gained in a machine learning-based webserver called “VLAmY-Pred” ( https://web.iitm.ac.in/bioinfo2/vlamy-pred/ ). The model shows prediction accuracy of 79.7% (sensitivity: 78.7% and specificity: 79.9%) with a ROC value of 0.88 on a dataset of 1828 variable region sequences of the antibody light chains. This model will be helpful towards improved prognosis for patients that may likely suffer from diseases caused by light chain amyloidosis, understanding origins of aggregation in antibody-based biotherapeutics, large-scale in-silico analysis of antibody sequences generated by next generation sequencing, and finally towards rational engineering of aggregation resistant antibodies.https://doi.org/10.1038/s41598-021-93019-9
collection DOAJ
language English
format Article
sources DOAJ
author Puneet Rawat
R. Prabakaran
Sandeep Kumar
M. Michael Gromiha
spellingShingle Puneet Rawat
R. Prabakaran
Sandeep Kumar
M. Michael Gromiha
Exploring the sequence features determining amyloidosis in human antibody light chains
Scientific Reports
author_facet Puneet Rawat
R. Prabakaran
Sandeep Kumar
M. Michael Gromiha
author_sort Puneet Rawat
title Exploring the sequence features determining amyloidosis in human antibody light chains
title_short Exploring the sequence features determining amyloidosis in human antibody light chains
title_full Exploring the sequence features determining amyloidosis in human antibody light chains
title_fullStr Exploring the sequence features determining amyloidosis in human antibody light chains
title_full_unstemmed Exploring the sequence features determining amyloidosis in human antibody light chains
title_sort exploring the sequence features determining amyloidosis in human antibody light chains
publisher Nature Publishing Group
series Scientific Reports
issn 2045-2322
publishDate 2021-07-01
description Abstract The light chain (AL) amyloidosis is caused by the aggregation of light chain of antibodies into amyloid fibrils. There are plenty of computational resources available for the prediction of short aggregation-prone regions within proteins. However, it is still a challenging task to predict the amyloidogenic nature of the whole protein using sequence/structure information. In the case of antibody light chains, common architecture and known binding sites can provide vital information for the prediction of amyloidogenicity at physiological conditions. Here, in this work, we have compared classical sequence-based, aggregation-related features (such as hydrophobicity, presence of gatekeeper residues, disorderness, β-propensity, etc.) calculated for the CDR, FR or VL regions of amyloidogenic and non-amyloidogenic antibody light chains and implemented the insights gained in a machine learning-based webserver called “VLAmY-Pred” ( https://web.iitm.ac.in/bioinfo2/vlamy-pred/ ). The model shows prediction accuracy of 79.7% (sensitivity: 78.7% and specificity: 79.9%) with a ROC value of 0.88 on a dataset of 1828 variable region sequences of the antibody light chains. This model will be helpful towards improved prognosis for patients that may likely suffer from diseases caused by light chain amyloidosis, understanding origins of aggregation in antibody-based biotherapeutics, large-scale in-silico analysis of antibody sequences generated by next generation sequencing, and finally towards rational engineering of aggregation resistant antibodies.
url https://doi.org/10.1038/s41598-021-93019-9
work_keys_str_mv AT puneetrawat exploringthesequencefeaturesdeterminingamyloidosisinhumanantibodylightchains
AT rprabakaran exploringthesequencefeaturesdeterminingamyloidosisinhumanantibodylightchains
AT sandeepkumar exploringthesequencefeaturesdeterminingamyloidosisinhumanantibodylightchains
AT mmichaelgromiha exploringthesequencefeaturesdeterminingamyloidosisinhumanantibodylightchains
_version_ 1721320295119192064